Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Validea
$12.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Enanta Pharmaceuticals announces U.S. FDA grants priority review to abbvie for investigational, all-oral, interferon-free regimen for genotype 1 chronic hepatitis C


Friday, 13 Jun 2014 03:39pm EDT 

Enanta Pharmaceuticals Inc:Announced that the New Drug Application for AbbVie's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus infection has been accepted by the U.S. Food and Drug Administration and has been granted priority review.Three direct-acting antiviral investigational regimen consists of the fixed-dose combination of ABT-450/ritonavir (150/100mg) co-formulated with ombitasvir (ABT-267) 25mg, dosed once daily, and dasabuvir (ABT-333) 250mg with or without ribavirin (weight-based), dosed twice daily. 

Company Quote

40.13
0.31 +0.78%
4:00pm EDT